We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




POC Rapid Diagnostics Platform Leverages Graphene-Based Biosensors for Real-Time Disease Detection

By LabMedica International staff writers
Posted on 08 Jun 2023
Print article
Image: Graphene-based biosensors for medical devices can be used to diagnose a variety of diseases at POC (Photo courtesy of Freepik)
Image: Graphene-based biosensors for medical devices can be used to diagnose a variety of diseases at POC (Photo courtesy of Freepik)

A revolutionary graphene-based technology enables testing for a broad range of indications using a variety of sample types in less than five minutes at POC, placing high-performance diagnostics directly in the hands of medical professionals.

GrapheneDx (Boston MA, USA), an in vitro diagnostics company, is focusing on improving diagnostic capability at the point of care by industrializing graphene-based biosensors for medical devices used to diagnose a variety of diseases. Known for its superior electrical properties, graphene - a single-atom, thick layer of carbon - enables the highly accurate detection of diverse biomolecules. The medical devices developed by GrapheneDx are designed to match lab-quality accuracy, yield results in less than five minutes, and be easy enough to be used in professional healthcare settings.

GrapheneDx has developed the GFET platform which demonstrates remarkable versatility in diagnosing various conditions such as sexually transmitted infections, respiratory and cardiac diseases, concussion, and more, using different sample types like stool, urine, swabs, blood, etc., with minimal or no sample preparation. Moreover, the platform has the capability to concurrently multiplex multiple analytes using a single patient sample. The first tests introduced by GrapheneDx will focus on the diagnosis of sexually transmitted infections, specifically Chlamydia and Gonorrhea, utilizing a noninvasive, easy-to-collect urine sample.

Related Links:
GrapheneDx 

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Creatine Kinase-MB Assay
CK-MB Test
New
Silver Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.